Aileron Therapeutics (NASDAQ:ALRN) PT Raised to $19.00

Aileron Therapeutics (NASDAQ:ALRN) had its target price lifted by stock analysts at LADENBURG THALM/SH SH from $9.00 to $19.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. LADENBURG THALM/SH SH’s price target would indicate a potential upside of 347.06% from the stock’s previous close.

Aileron Therapeutics Price Performance

NASDAQ ALRN opened at $4.25 on Thursday. The stock’s fifty day moving average price is $5.39 and its 200 day moving average price is $3.59. Aileron Therapeutics has a 1 year low of $1.01 and a 1 year high of $7.12. The company has a market cap of $20.78 million, a price-to-earnings ratio of -1.26 and a beta of 2.22.

Hedge Funds Weigh In On Aileron Therapeutics

Several hedge funds have recently made changes to their positions in ALRN. Renaissance Technologies LLC grew its position in Aileron Therapeutics by 65.5% during the 3rd quarter. Renaissance Technologies LLC now owns 190,691 shares of the company’s stock worth $39,000 after purchasing an additional 75,500 shares during the period. Envestnet Asset Management Inc. grew its position in Aileron Therapeutics by 52.9% during the 3rd quarter. Envestnet Asset Management Inc. now owns 184,022 shares of the company’s stock worth $38,000 after purchasing an additional 63,651 shares during the period. Geode Capital Management LLC grew its position in Aileron Therapeutics by 23.2% during the 1st quarter. Geode Capital Management LLC now owns 54,799 shares of the company’s stock worth $68,000 after purchasing an additional 10,311 shares during the period. Sigma Planning Corp acquired a new stake in Aileron Therapeutics during the 4th quarter worth about $51,000. Finally, Texas Capital Bank Wealth Management Services Inc acquired a new stake in Aileron Therapeutics during the 4th quarter worth about $48,000. 90.89% of the stock is owned by institutional investors and hedge funds.

About Aileron Therapeutics

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.